Author

Iona Ashworth

Brighton and Sussex Medical School

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Aimilia VareliiD· 1 shared Amarpreet DeviiD· 1 shared Andrea G. S. PepperiD· 1 shared Chris J. PepperiD· 1 shared David M. RossiD· 1 shared Eleni E LadikouiD· 1 shared Emma KennedyiD· 1 shared Fabio A. SimoesiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aimilia VareliORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A novel in-vitro model of the bone marrow microenvironment in AML identifies CD44 and Focal Adhesion Kinase as therapeutic targets to reverse cell adhesion-mediated drug resistance

Eleni E Ladikou, K. Sharp, Fabio A. Simoes, John R Jones, Thomas A. Burley, Lauren Stott, Aimilia Vareli, Emma Kennedy, Sophie Vause, Timothy J. T. Chevassut, Amarpreet Devi, Iona Ashworth, David M. Ross, Tanja Nicole Hartmann, Simon A. Mitchell, , Andrea G. S. Pepper

This study identifies CD44 and FAK as therapeutic targets to reverse adhesion-mediated drug resistance in AML by developing an in-vitro BMME model and testing their synergistic effects.

Cancers · Jan 3, 2025Peer-reviewedCancer Biology